|
|
|
|
HemaQuest Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
Boston (OBBeC) - The U.S.Food and Drug Administration (FDA) has awarded HemaQuest Pharmaceuticals orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally administered therapeutic...
|
|
|
HemaQuest gets orphan drug status for blood disorders drug
HemaQuest Pharmaceuticals announced that the US Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anaemia and beta thalassemia for HQK-1001, which is an orally administered...
|
|
|
HemaQuest wins orphan drug designations for anemia drug
BOSTON, Mass.- HemaQuest Pharmaceuticals yesterday announced that the FDA has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally administered therapeutic...
|
|
|
HemaQuest wins orphan drug designations for anemia drug
HemaQuest has recently completed Phase I clinical trials of HQK-1001 in healthy subjects and plans to begin clinical studies of this compound in both sickle cell anemia and beta thalassemia in the near future.The compound's...
|
|
|
HemaQuest Pharmaceuticals receives Orphan Drug designations for therapeutic to treat Hemoglobin Disorders
BOSTON - HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally...
|
|
|
HemaQuest Pharmaceuticals: HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Trea
- HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally...
|
|
|
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
- HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally...
|
|
|
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally...
|
|
|
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
BOSTON, MA, November 4 / MARKET WIRE/ -- HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia...
|
|
|
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
-- HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally...
|
|
|
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally...
|
|
|
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
BOSTON, MA, November 4 / MARKET WIRE/ -- HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia...
|
|
|
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
-- HemaQuest Pharmaceuticals today announced that the U.S.Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1, 2008 /PRNewswire-FirstCall/ -- Schering...
|
|
|
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C P
- Higher Sustained Virological Response Rates Recognized as Marker of Treatment Success - SAN FRANCISCO, Calif., Nov.1 /PRNewswire/ -- A new, independently-conducted study being presented at the 59th Annual Meeting of the American...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C P
- Higher Sustained Virological Response Rates Recognized as Marker of Treatment Success - SAN FRANCISCO, Calif., Nov.1 /PRNewswire/ -- A new, independently-conducted study being presented at the 59th Annual Meeting of the American...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C P
- Higher Sustained Virological Response Rates Recognized as Marker of Treatment Success - SAN FRANCISCO, Calif., Nov.1 /PRNewswire/ -- A new, independently-conducted study being presented at the 59th Annual Meeting of the American...
|
|
|
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 T
Interim results of HCV SPRINT-1 study presented at AASLD annual meeting Pivotal Phase III studies ongoing in treatment naive patients and those who failed prior treatment SAN FRANCISCO, Nov.1 /PRNewswire-FirstCall/ -- Schering-Plough...
|
|
|
Treating Neovascular Peripheral Retinal Diseases
MARENA PATRONAS, MD JOSEPH M.CONEY, MD LAWRENCE J. SINGERMAN, MD, FACS Pathological processes in the peripheral retina have attracted the attention of both clinical investigators and practicing ophthalmologists for many years.
|
|
|
Deferiprone glucuronidation by human tissues and recombinant UGT1A6: an in vitro investigation of genetic and
Drug Metabolism and Disposition Fast Forward This Article Google Scholar Received for publication June 27, 2008.Revised October 24, 2008. Accepted for publication October 24, 2008. Marie-Odile Benoit-Biancamano 1, John Connelly 2,...
|
|
|
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
MELBOURNE, Australia, Oct.27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured.
|
|
|
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
MELBOURNE, Australia, Oct.27 /PRNewswire/ -- MuriGen Therapeutics today announced that its collaboration with CSL for the development of a new class of drugs that target arthritis and other inflammatory diseases has been restructured.
|
|
|
WEHI Spin-Out MuriGen Restructures G-CSF Antagonist Program With CSL
MELBOURNE, Australia The collaboration was initially established in February 2006 The collaboration built on the discovery by Professor Ian Wicks Under the terms of the restructure, CSL will now take full control of the program, including...
|
